https://scholars.lib.ntu.edu.tw/handle/123456789/551470
標題: | The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis | 作者: | Hwang J.-S. Chin L.-S. Chen J.-F. Yang T.-S. Chen P.-Q. KEH-SUNG TSAI Leung P.C. |
關鍵字: | Bone mineral density; Osteoporosis; Zoledronic acid | 公開日期: | 2011 | 卷: | 29 | 期: | 3 | 起(迄)頁: | 328-333 | 來源出版物: | Journal of Bone and Mineral Metabolism | 摘要: | The aim of this study was to assess the efficacy and safety of a once-yearly zoledronic acid treatment for Chinese women with postmenopausal osteoporosis in Taiwan and Hong Kong. This post hoc subpopulation analysis, from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly Pivotal Fracture Trial, enrolled 323 Chinese women with osteoporosis who were randomly given either annual infusions of zoledronic acid or placebo for 3 consecutive years. The incidence of fractures and changes in bone mineral density (BMD) were measured; adverse events (AEs) and tolerability were recorded and assessed. The results of this study at 36 months demonstrate that there was a significantly reduced risk of morphometric vertebral fracture and clinical vertebral fracture in subjects treated with zoledronic acid (P < 0.05). In addition, there were significant increases of BMD by 4.9%, 4.3%, and 7.0% in the total hip, femoral neck, and trochanter, respectively, in the zoledronic acid group compared with the placebo group (P < 0.001 for all comparisons). The incidences of AEs were comparable between the two groups. Thus, once-yearly zoledronic acid treatment showed bone protection effects by reducing the risk of vertebral fracture and increasing BMD in Chinese women with postmenopausal osteoporosis. ? 2010 The Japanese Society for Bone and Mineral Research and Springer. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/551470 | ISSN: | 0914-8779 | DOI: | 10.1007/s00774-010-0223-y | SDG/關鍵字: | placebo; zoledronic acid; adult; aged; arthralgia; article; bone density; Chinese; clinical article; controlled clinical trial; controlled study; creatinine clearance; drug effect; drug safety; drug tolerability; drug withdrawal; female; femur neck; fever; headache; hip; human; malaise; morphometrics; myalgia; outcome assessment; postmenopause osteoporosis; priority journal; risk reduction; side effect; treatment duration; vertebra fracture; Aged; Aged, 80 and over; Asian Continental Ancestry Group; Bone Density; Bone Density Conservation Agents; China; Demography; Diphosphonates; Female; Femoral Neck Fractures; Hip Fractures; Humans; Imidazoles; Incidence; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。